Overview
VRTX market data
Price History
VRTX price chart
Valuation & Profitability
- P/E (TTM)
- 27.78 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $15.32 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.30 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $362.50 – $533.67 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $120.5K · P/B 6.16 · P/S 9.86.
Company News
Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover TargetThe Motley Fool · Jul 30, 2026, 11:15 PM
VHT vs. PBE: Which Health Care ETF Is the Better Buy?The Motley Fool · Jul 30, 2026, 2:15 PM
AbCellera Announces $28M Upfront Vertex Collaboration On Multispecific T-Cell Engagers For Autoimmune Diseases, Eligible For Milestone Payments And Tiered RoyaltiesBenzinga · Jul 29, 2026, 11:06 AM
Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and FeesThe Motley Fool · Jul 28, 2026, 1:01 PM
iShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026?The Motley Fool · Jul 23, 2026, 8:15 PM
Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product DevelopmentGlobenewswire Inc · Jul 23, 2026, 11:00 AM
These 7 Small Caps Are on Fire as the Second Half Begins: Here’s WhyBenzinga · Jul 21, 2026, 7:52 PM
Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?The Motley Fool · Jul 13, 2026, 7:15 PM
UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $585Benzinga · Jul 13, 2026, 6:18 PM
Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $560Benzinga · Jul 13, 2026, 4:31 PM